ArticleDiscover oncology2025
Decreased IL20RA expression serves as a predictor of unfavorable prognosis in endometrial cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveOverexpression of interleukin-20 receptor A (IL20RA) has been implicated in promoting tumor growth, metastasis, and unfavorable prognosis of various malignancies. However, its role in endometrial cancer (EC) remains unexplored. This study aims to comprehensively analyze the functional roles and clinical significance of IL20RA expression in EC.
methodsWe utilized data from TCGA and XENA databases to compare IL20RA levels between normal uterine tissues and EC tissues. The association between IL20RA expression and clinical characteristics, as well as patient prognosis, was further evaluated. Using ROC analysis, COX regression, and survival analyses, we assessed the relevance of reduced IL20RA expression to diagnostic and prognostic outcomes in EC. Additionally, a prognostic nomogram based on IL20RA expression was developed to predict patient survival.
resultsIL20RA expression was significantly downregulated in EC tissues. Reduced IL20RA levels were correlated with cancer diagnosis, advanced clinical stage, age, weight, BMI, histological subtype, tumor invasiveness, and unfavorable prognosis. Furthermore, IL20RA was identified as an independent risk factor for unfavorable DSS and PFI in EC patients. The constructed prognostic nomogram demonstrated the DSS and disease progression in EC.
conclusionIL20RA expression is markedly suppressed in EC. Its downregulation is associated with both diagnosis and prognosis, suggesting that IL20RA may serve as a potential prognostic biomarker for EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.